Prestige Biologics Achieves Record-High Quarterly Results
Prestige Biologics has surpassed 10 billion won in quarterly sales for the first time.
According to Prestige Biologics on August 19, revenue for the fourth quarter of fiscal year 2026 (April to June 2026) reached 11.47 billion won. This figure is more than five times higher than the previous quarter's sales of 2.27 billion won.
During fiscal year 2026, Prestige Biologics signed a total of six new contract manufacturing (CDMO) agreements with domestic and international clients, amounting to approximately 41.2 billion won. The company has continued to expand its order base, and these new contracts have been sequentially converted into production and sales, positively impacting this quarter’s performance.
Hot Picks Today
"Ssangyong C&E to Leave Seoul Headquarters With 120 Staff and Move to Donghae City... First Major Gamble in 60 Years"
- [Exclusive] "I Accidentally Pressed the Accelerator Pedal Because I'm a Beginner" ... Hyundai Unveils Advanced Safety Technology to Relieve Driver Anxiety
- Listening to Your Favorite Artist's New Release While Driving: "The Surprising Rise in Fatal Accidents"
- "Turned 600 Million Won into 100-Fold Profit"…Chinese Actress Zhang Ziyi Scores 63.5 Billion Won Windfall from Investment, Not Acting
- "Persistent Musty Odor Despite Repeated Washing" ... Tackling the Source of Stubborn Sweat Smells in Workout Clothes Boosted Sales by 316% [Interview]
Jinwoo Kim, CEO of Prestige Biologics, stated, "Despite the sales growth, the increase in losses was primarily due to impairment of inventory assets, convertible bonds (CB), and certain production facilities. The actual impact on cash flow is limited. Surpassing 10 billion won in fourth-quarter sales demonstrates that our ongoing expansion of the order base is now being reflected in our results."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
